SKKU researchers have made a groundbreaking discovery in the field of cancer immunotherapy, developing the world's first oral microbiome-based nanomedicine. This innovative approach harnesses the power of gut bacteria metabolites to supercharge the body's immune response against cancer. The research, led by Professor Young Seok Cho and Professor James J. Moon, has been published in Nature Nanotechnology, a prestigious journal in the field of nanoscience and medicine.
The study focuses on a microbial metabolite called 3,4-dihydroxybenzoic acid (DHB), which has been found to act as a potent immune booster. DHB promotes 'stemness' in CD8+ T cells, the immune cells responsible for destroying cancer. By blocking metabolic exhaustion, DHB enables T cells to remain active and attack cancer cells for extended periods. However, natural DHB has a short half-life, breaking down rapidly in the body.
To overcome this challenge, the research team applied nanotechnology. They chemically modified DHB into a stable prodrug and encapsulated it in an oral nano-emulsion, named Prodrug 201. This innovation significantly increases the drug's bioavailability, allowing it to stay in the bloodstream longer and be more effectively absorbed by the body. In animal models with colorectal cancer, melanoma, and breast cancer, the oral nanomedicine directed stem-like T cells directly to tumor sites, resulting in dramatic tumor shrinkage.
When combined with immune checkpoint blockade therapy, the oral nanomedicine completely eradicated tumors in test models and created long-term immune memory to prevent cancer recurrence. This breakthrough has the potential to revolutionize cancer immunotherapy, making it more effective and accessible to a wider range of patients. Professor Cho emphasizes the significance of this discovery, stating that it translates the understanding of gut microbial metabolism into a safe and scalable nanomedicine, paving the way for next-generation microbiome-based cancer immunotherapies.
This research highlights the potential of harnessing the body's natural microbiome to enhance cancer treatment. By utilizing nanotechnology, scientists can overcome the limitations of natural DHB, making it a more viable option for cancer patients. The development of oral nanomedicine represents a significant step forward in the fight against cancer, offering a promising new avenue for immunotherapy.
